Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
<h4>Background</h4>Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized cont...
Guardado en:
Autores principales: | Yukai Liu, Ken Chen, Xun Kou, Yu Han, Lin Zhou, Chunyu Zeng |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ac1000c01c4f417ab5757b0ddd8bb03f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
por: Karl Andersen
Publicado: (2009) -
Dosing Time Matters? Nighttime vs. Daytime Administration of Nifedipine Gastrointestinal Therapeutic System (GITS) or Amlodipine on Non-dipper Hypertension: A Randomized Controlled Trial of NARRAS
por: Jing Liu, et al.
Publicado: (2021) -
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
por: Kristin Schmerbach, et al.
Publicado: (2010) -
Effects of Danshen tablets on pharmacokinetics of amlodipine in rats
por: Haixia Zhang, et al.
Publicado: (2019) -
Effects of Three Traditional Chinese Fitness Exercises Combined with Antihypertensive Drugs on Patients with Essential Hypertension: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Lulu Dai, et al.
Publicado: (2021)